PGEN · Precigen
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $5.57
Note written ·
Price against the kill line
18.5% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $5.57, on record since 11 November 2026. The shares are down 30.7% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $5.57, which would recover the drop that followed the 4 November 2026 report (the shares closed at $5.05 that day) and show the shares leading the S&P 500.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 4 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 74.1
- Revenue, change on a year (%)
- +2437.6
- Operating margin (%)
- 52.1
- Free cash flow, four quarters ($M)
- −74.3
- Net cash, cash less debt ($M)
- −43.3
- Price to earnings (×)
- 66.7
- Enterprise value to sales (×)
- 10.6
- Enterprise value to operating income (×)
- 49.7
All filed numbers
What Precigen reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 74.1 | +2437.6 | 52.1 |
| first filed | 55.0 | +6322.7 | 41.2 |
| first filed | 23.3 | +1633.9 | −25.8 |
| first filed | 4.6 | — | −474.6 |
| first filed | 2.9 | — | −1180.0 |
| first filed | 0.9 | — | −3710.7 |
| Pre-tax income ($M) | 36.0 |
| Net income ($M) four quarters: 24.4 | 35.8 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +37.1 |
| Operating cash flow ($M) | −73.2 |
| Capital spending ($M) | 1.1 |
| Free cash flow ($M) | −74.3 |
| Cash and short-term investments ($M) | 51.0 |
| Debt ($M) long-term debt | 94.3 |
| Net cash, cash less debt ($M) | −43.3 |
| Deferred revenue ($M) −63.7% on a year | 0.2 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 96.5 |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 83.8 |
| Market value ($M) | 1,628 |
| Enterprise value, market value plus net debt ($M) | 1,671 |
| Enterprise value to sales (×) | 10.6 |
| Enterprise value to operating income (×) | 49.7 |
| Price to earnings (×) | 66.7 |
| Price to book value (×) | 19.4 |
| Free-cash-flow yield (%) | −4.6 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 12.9% of shares outstanding sold short, 10.2 days of average trading to cover, −2.4% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $25K | $2.3M |
| 12 monthsfrom | $25K | $44.8M |
The thesis
Precigen's PAPZIMEOS launch is profitable and generated cash a quarter early, but sequential revenue growth slowed to 37% and Inovio's rival drug is approved. The shares are more likely to lag the S&P 500 than lead it over the next three months. Fourth-quarter PAPZIMEOS revenue, and how quickly Inovio's launch takes patients, settle it.
Precigen reported third-quarter 2026 results on 4 November 2026. Total revenue was $74.148 million and PAPZIMEOS net product revenue was $72.9 million, up 37% from the second quarter (Form 8-K, Ex-99.1). Second-quarter growth had been about 146% sequentially, from $21.6 million in the first quarter to $53.1 million (company releases). Consensus figures differed by source: Benzinga's headline put the revenue estimate at $71.558 million, while Zacks had $75.43 million.
The shares closed at $5.05 on 4 November 2026, the session before the after-close report. They closed at $4.22 on 5 November 2026, the first session after it, and at $4.72 on 11 November 2026. That is 47.4% below the 52-week intraday high of $8.98 set on 30 September 2026. The market is pricing a slowing launch and a second approved competitor, not the quarter's $35.8 million of net income.
Bullish and bearish views on Precigen, Inc.
The bull case on Precigen, Inc. (PGEN), in brief: profit and cash flow arrived early. The bear case: a second RRP drug is approved.
Bull case
- Profit and cash flow arrived early. Q3 net income was $35.8 million, or $0.08 per diluted share, and operating cash flow was $11.9 million, a full quarter ahead of the company's year-end guidance (Form 8-K, 4 November 2026).
- Patient numbers keep rising. "Well over 500" patients have started PAPZIMEOS and "well over 300" have completed treatment, with a redosing study enrolling (Form 8-K, 4 November 2026). A report of the call cited hub registrations above 600 and uptake in patients with fewer than three prior-year surgeries.
- Coverage and exclusivity are in place. Payer coverage spans about 315 million lives and a permanent billing code has applied since April (report of the 4 November 2026 call). Orphan drug exclusivity runs to 14 August 2032 (company release, 4 August 2026).
- Analysts remain constructive. Citizens maintained Market Outperform and raised its price target to $12 on 5 November 2026 (Benzinga headline).
- A director bought shares. Nancy Agee bought 3,411 shares at $7.23 on 21 August 2026 (SEC Form 4, filed 25 August 2026).
Bear case
- A second RRP drug is approved. Inovio announced FDA accelerated approval of VOCERYQ for recurrent respiratory papillomatosis (RRP) on 30 October 2026 (Inovio press release). A report of the Q3 call says Inovio is expected to launch in the new year, so adult starts may split between two products.
- Growth slowed sharply. Sequential revenue growth fell from roughly 146% in Q2 to 37% in Q3 (Form 8-K and company releases). No formal fourth-quarter guidance was given (report of the 4 November 2026 call).
- Receivables are outrunning cash. Trade receivables were $96.5 million at 30 September 2026, up from $71.9 million at 30 June 2026, against $51.0 million of cash and investments (Form 8-K, 4 November 2026).
- One product carries the company. PAPZIMEOS was $72.9 million of $74.148 million Q3 revenue (Form 8-K, 4 November 2026).
- Insiders have sold into strength. Director Jeffrey Kindler sold 185,000 shares at $7.44 on 26 August 2026, and the chief operating and commercial officers sold under Rule 10b5-1 plans at $7.50 in August (SEC Form 4 filings).
Price setup
The last close was $4.72 on 11 November 2026. That is below the 50-day average of $6.84 and below the 200-day average of $5.28, both adjusted closes as of 11 November 2026. The three-month change is −27.3%, from a $6.49 close on 13 August 2026.
The 52-week intraday high is $8.98 (30 September 2026) and the 52-week closing low is $3.10 (25 March 2026). Closes since the report ran $4.22 (5 November 2026), $4.47 (6 November 2026), $4.73 (9 November 2026), $4.52 (10 November 2026) and $4.72 (11 November 2026). The shares have held in a narrow range below the 200-day average since the report, and have not yet closed back above it.
Catalysts ahead
- Undated (forthcoming R&D Day): Precigen R&D Day with new Phase 2 PRGN-2009 data in newly diagnosed HPV-associated oropharyngeal cancer. Would test whether the pipeline gives the shares a second driver beyond PAPZIMEOS; the company has given no date.
- ~January 2027 (est.): Expected start of Inovio's VOCERYQ launch in the US. Early uptake data would show how much new adult RRP demand moves away from PAPZIMEOS.
- ~March 2027 (est.): Precigen fourth-quarter and full-year 2026 results. Shows whether PAPZIMEOS revenue grew beyond Q3's $72.9M and whether receivables of $96.5M turned into cash.
What would change the view
A daily close above $5.57, which would recover the drop that followed the 4 November 2026 report (the shares closed at $5.05 that day) and show the shares leading the S&P 500.
What it trades with
PGEN trades on one drug's launch and on its rival. Inovio shares were reported trading more than 230% higher premarket on 2 November 2026 while Precigen fell, and TIKR reported Precigen down 26% in trading after the approval. The two shares move in opposite directions on RRP news.
Small-cap drug developers also share funding and interest-rate sensitivity, which affects how the market values a company with $96.5 million of receivables still to collect.
The evidence, claim by claim (7)
- Q3 2026 total revenue $74.148M; PAPZIMEOS net product revenue $72.9M, up 37% sequentially; launch-to-date net product revenue $151M. Precigen Form 8-K Ex-99.1, Q3 2026 results · as of
- Q3 2026 net income $35.8M ($0.08 per diluted share); operating cash flow $11.9M, a quarter ahead of the year-end cash-flow guidance. Precigen Form 8-K Ex-99.1, Q3 2026 results · as of
- Cash, cash equivalents and investments $51.0M and trade receivables $96.5M at 30 September 2026, versus $71.9M of receivables at 30 June 2026. Precigen Form 8-K Ex-99.1; Form 10-Q for Q2 2026 · as of
- 'Well over 500' patients have started PAPZIMEOS and 'well over 300' have completed treatment; the redosing study is enrolling. Precigen Form 8-K Ex-99.1, Q3 2026 results · as of
- Inovio announced FDA accelerated approval of VOCERYQ (INO-3107) for adults with RRP. Inovio press release · as of
- Citizens maintained Market Outperform on Precigen and raised its price target to $12 after the Q3 results. Benzinga, 'Citizens Maintains Market Outperform on Precigen, Raises Price Target to $12' · as of
- Director Jeffrey Kindler sold 185,000 shares at $7.44 on 26 August 2026. SEC Form 4 filed 28 August 2026 · as of
Sources
- PRECIGEN, INC. - Form 8-K - FY2026 · sec.gov
- Precigen narrowly misses as PAPZIMEOS growth slows and a competitor looms even as cash flow turns positive early · finviz.com
- Precigen Sinks 26% as Inovio Wins FDA Approval for Papzimeos Rival Days Before Earnings · tikr.com
- Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance · finviz.com
Related · shared themes
TVTX
Travere Therapeutics
Travere Therapeutics' FILSPARI kidney-drug sales beat the third-quarter benchmark at $200.2 million, but new patient start forms slipped to…
ABEO
Abeona Therapeutics
Abeona Therapeutics' ZEVASKYN revenue grew 18% to $13.5 million in the third quarter but missed estimates, and a $3.75-a-share placement…
ARCT
Arcturus Therapeutics Holdings
Arcturus Therapeutics has cash into 2028 but no dated FDA path for ARCT-810 and no dated Phase 3 decision for ARCT-032, so the shares are…
DSGN
Design Therapeutics
Design Therapeutics' shares are more likely to lag the S&P 500: a new $200 million stock-sale program adds supply while DT-216P2's…
See also · stocks to watch